Stoke Therapeutics (NASDAQ:STOK) Trading 6.9% Higher - What's Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s share price rose 6.9% during mid-day trading on Wednesday . The stock traded as high as $10.00 and last traded at $10.50. Approximately 13,795 shares changed hands during trading, a decline of 98% from the average daily volume of 822,257 shares. The stock had previously closed at $9.82.

Analyst Ratings Changes

A number of brokerages have weighed in on STOK. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Chardan Capital started coverage on Stoke Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating and a $24.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $21.29.

Stoke Therapeutics Price Performance

The firm's 50-day moving average price is $11.09 and its 200-day moving average price is $12.73. The company has a market cap of $549.72 million, a price-to-earnings ratio of -4.99 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 2,586 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the sale, the insider now owns 44,746 shares in the company, valued at $581,250.54. The trade was a 5.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the sale, the chief executive officer now directly owns 68,671 shares in the company, valued at $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,849 shares of company stock valued at $809,421. Corporate insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the period. RTW Investments LP increased its position in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after buying an additional 427,447 shares during the period. Jane Street Group LLC increased its position in Stoke Therapeutics by 338.2% in the third quarter. Jane Street Group LLC now owns 330,442 shares of the company's stock worth $4,061,000 after buying an additional 255,028 shares during the period. Millennium Management LLC lifted its stake in Stoke Therapeutics by 528.6% in the second quarter. Millennium Management LLC now owns 289,067 shares of the company's stock valued at $3,905,000 after buying an additional 243,083 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new position in shares of Stoke Therapeutics during the third quarter valued at $2,170,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.